MAINZ, Germany, December 12, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18th, 2023. The inauguration takes place on the occasion of the set-up of the containers for the first manufacturing unit called BioNTainer.
BioNTech invites media and the general public to join a live stream of the event on the same day at 2:00 pm CET. The statements of high-level dignitaries including official government representatives as well as members of BioNTech’s board will be broadcasted in addition to the ceremonial ribbon cutting. The live stream will be available via this link, which will be activated on the event day.
A replay of the stream will be available via the “Events & Presentations” page of the Investor Relations section of the Company’s website at www.BioNTech.com. This will be available shortly after the conclusion of the event on the Company’s website for seven days following the event.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron, Sanofi and Pfizer.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$114.47 |
| Daily Change: | -3.06 -2.60 |
| Daily Volume: | 696,985 |
| Market Cap: | US$27.220B |
September 05, 2024 July 30, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
